Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

Haro, Josep Maria; Novick, Diego; Belger, Mark; Jones, Peter B.

doi:10.1016/j.eurpsy.2005.12.001

Cited by 49Schizophrenia research and treatmentMedication Adherence and ComplianceBipolar Disorder and Treatment

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

Haro, Josep Maria, Novick, Diego, Belger, Mark, Jones, Peter B.·2006·European Psychiatry

DOI 10.1016/j.eurpsy.2005.12.001

Open this paper in CoChat — free account

Abstract

Antipsychotic medication maintenance and the factors influencing it were analyzed using data from the SOHO study, a large observational study of the outcomes of antipsychotic treatment for schizophrenia in Europe. A total of 7186 adult patients in the outpatient setting who were initiating or changing their antipsychotic medication and who were prescribed only one antipsychotic after the baseline visit were analyzed. Medication maintenance at 12 months varied with the type of antipsychotic prescribed, being highest with clozapine (79.5%) and olanzapine (77.0%), and lowest with quetiapine (51.4%) and amisulpride (58.2%). Multiple logistic regression analysis demonstrated that the type of antipsychotic prescribed at baseline was the most important predictor of medication maintenance. Alcohol dependency, taking mood stabilizers, compulsory admission or arrest in the previous 6 months, greater clinical severity, and changing antipsychotic medication due to lack of effectiveness at baseline predicted a higher frequency of medication discontinuation in the subsequent 12 months. In contrast, medication maintenance was higher among patients who were treatment naïve at baseline, socially active or who had loss of libido at baseline. The findings from this study should be interpreted conservatively because of its non-randomized observational design.

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2005.12.001

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The adverse events in Pu et al. may be related to participants' use of olanzapine for at least 9 months, which increased their sensitivity to minor adverse reactions.
“This may be related to the participants’ use of the antipsychotic drug olanzapine for at least 9 months, which increased their sensitivity to minor adverse reactions (Haro et al., 2006).”
From Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials (2025) · cites this paper as Haro et al., 2006

Untitled work
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
Clinical Global Impression
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441 · see citing works
The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia
Haro, J. M., Kamath, S., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodríguez, M. J., Rele, R., Orta, J., Kharbeng, A., et al. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.107.s416.5.x · Cited by 659 · see citing works
Self-citation
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
Stroup, T., Mcevoy, J., Swartz, M., Byerly, M., Glick, I., Cañive, J., McGee, M., Simpson, G., Stevens, M., & Lieberman, J. (2003) · Schizophrenia bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 647 · see citing works
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Chakos, M., Lieberman, J. A., Hoffman, E. B., Bradford, D. W., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 632 · see citing works
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · see citing works
Predictors of Noncompliance in Patients With Schizophrenia
Perkins, D. O. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1206 · Cited by 546 · see citing works
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Bilder, R. M., Hinrichsen, G. A., & Lieberman, J. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00312-7 · Cited by 290 · see citing works
Sexual dysfunction in male schizophrenic patients.
Aizenberg, D., Zemishlany, Z., Dorfman-Etrog, P., & Weizman, A. (1995) · PubMed · Cited by 213 · see citing works
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
Basile, V. S., Masellis, M., McIntyre, R. S., Meltzer, H. Y., Lieberman, J. A., & Kennedy, J. L. (2001) · PubMed · Cited by 211 · see citing works
Sexual dysfunction and antipsychotic treatment
Cutler, A. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00113-0 · Cited by 176 · see citing works
Detection and management of comorbidity in patients with schizophrenia
Green, A. I., Canuso, C. M., Brenner, M. J., & Wojcik, J. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00014-x · Cited by 159 · see citing works
Predictors of Risk of Nonadherence in Outpatients With Schizophrenia and Other Psychotic Disorders
Weiss, K. A., Smith, T. E., Hull, J. W., Piper, A. C., & Huppert, J. D. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006943 · Cited by 133 · see citing works
The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment
Haro, J. M., Edgell, E. T., Jones, P. B., Alonso, J., Gavart, S., Gregor, K. J., Wright, P., Knapp, M. R. J., & on behalf of the SOHO Study Group (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00064.x · Cited by 114 · see citing works
Self-citation
Effectiveness of antipsychotic treatment for schizophrenia: 6‐month results of the Pan‐European Schizophrenia Outpatient Health Outcomes (SOHO) study
Haro, J. M., Edgell, E. T., Novick, D., Alonso, J., Kennedy, L., Jones, P. B., Ratcliffe, M., Breier, A. F., & SOHO advisory board (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00450.x · Cited by 99 · see citing works
Self-citation
A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 87 · see citing works
Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes
Marder, S. R., Glynn, S. M., Wirshing, W. C., Wirshing, D. A., Ross, D., Widmark, C., Mintz, J., Liberman, R. P., & Blair, K. E. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1405 · Cited by 84 · see citing works
Sexual behavior and sexual problems among patients with severe chronic psychoses
Raja, M., & Azzoni, A. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00009-9 · Cited by 73 · see citing works
Olanzapine vs. other antipsychotics in actual out‐patient settings: six months tolerability results from the European Schizophrenia Out‐patient Health Outcomes study
Lambert, M., Haro, J. M., Novick, D., Edgell, E. T., Kennedy, L., Ratcliffe, M., & Naber, D. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00451.x · Cited by 72 · see citing works
Self-citation
[Relationships between insight and medication adherence in subjects with psychosis].
Droulout, T., Liraud, F., & Verdoux, H. (2004) · PubMed · Cited by 63 · see citing works
The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment
Haro, J. M., Edgell, E. T., Frewer, P., Alonso, J., Jones, P. B., & on behalf of the SOHO Study Group (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.107.s416.4.x · Cited by 56 · see citing works
Self-citation
Clozapine in elderly psychiatric patients: Tolerability, safety, and efficacy
Barak, Y., Wittenberg, N., Naor, S., Kutzuk, D., & Weizman, A. (1999) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(99)90134-7 · Cited by 55 · see citing works
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders
Glick, I. D., & Berg, P. H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200203000-00004 · Cited by 51 · see citing works
Choice of maintenance medication for schizophrenia.
Davis, J. M., & Chen, N. (2003) · PubMed · Cited by 38 · see citing works
Choosing Antipsychotic Maintenance Therapy - A Naturalistic Study
Tavčar, R., Dernovšek, M. Z., & Zvan, V. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-7969 · Cited by 23 · see citing works
Old versus new: weighing the evidence between the first- and second-generation antipsychotics
Davis, J. M., & Chen, N. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.002 · Cited by 22 · see citing works
Clinical Trial Response and Dropout Rates with Olanzapine versus Risperidone
Santarlasci, B., & Messori, A. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c291 · Cited by 22 · see citing works
Long‐term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study
Søholm, B., & Lublin, H. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00063.x · Cited by 17 · see citing works

Flagged first, then by citations

Sorted by citations

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Haro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 129 · see citing works
Self-citation
Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study
Novick, D., Haro, J. M., Suarez, D. L., Vieta, E., & Naber, D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.007 · Cited by 125 · see citing works
Self-citation
The SOHO (Schizophrenia Outpatient Health Outcome) Study
Haro, J. M., & Salvador‐Carulla, L. (2006) · CNS Drugs · doi:10.2165/00023210-200620040-00003 · Cited by 84 · see citing works
Self-citation
Clozapine as a first‐ or second‐line treatment in schizophrenia: a systematic review and meta‐analysis
Okhuijsen‐Pfeifer, C., Huijsman, E. A. H., Hasan, A., Sommer, I. E., Leucht, S., Kahn, R. S., & Luykx, J. J. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12954 · Cited by 81 · see citing works
Discontinuation of clozapine: a 15‐year naturalistic retrospective study of 320 patients
Davis, M. C., Fuller, M., Strauss, M., Konicki, P., & Jaskiw, G. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12233 · Cited by 74 · see citing works
Time to Discontinuation of Depot and Oral First-Generation Antipsychotics in the Usual Care of Schizophrenia
Zhu, B., Ascher‐Svanum, H., Shi, L., Faries, D. E., Montgomery, W. S., & Marder, S. R. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.3.315 · Cited by 66 · see citing works
Health-Related Quality of Life (HRQL) and Continuous Antipsychotic Treatment: 3-year Results from the Schizophrenia Health Outcomes (SOHO) Study
Alonso, J., Croudace, T. J., Brown, J., Gasquet, I., Knapp, M. R. J., Suarez, D. L., & Novick, D. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00495.x · Cited by 59 · see citing works
Self-citation
Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia
Wehmeier, P. M., Kluge, M., Schneider, E. M., Schacht, A., Wagner, T., & Schreiber, W. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.004 · Cited by 45 · see citing works
Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia
Üçok, A., Yağcioğlu, A. E. A., Yıldız, M., Kaymak, S. U., Saka, M. C., Taşdelen, R., Danacı, A. E., & Şenol, Ş. H. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.01.110 · Cited by 44 · see citing works
Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia
Attard, A., & Taylor, D. M. (2012) · CNS Drugs · doi:10.2165/11632020-000000000-00000 · Cited by 42 · see citing works
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patel, M. X., Bent‐Ennakhil, N., Sapin, C., di Nicola, S., Loze, J.-Y., Nylander, A.-G., & Heres, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02530-2 · Cited by 40 · see citing works
Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study
Novick, D., Haro, J. M., Suarez, D. L., Lambert, M., Lépine, J., & Naber, D. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0730-2 · Cited by 32 · see citing works
Self-citation
The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
Ciudad, A., Haro, J. M., Alonso, J., Bousoño, M., Suarez, D. L., Novick, D., & Gilaberte, I. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.09.008 · Cited by 29 · see citing works
Self-citation
Effectiveness of long-acting injectable antipsychotics: a clinical perspective
Castillo, E. G., & Stroup, T. S. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102086 · Cited by 28 · see citing works
Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study
Brnabic, A. J. M., Kelin, K., Ascher‐Svanum, H., Montgomery, W. S., KADZIOLA, Z. A., & Karagianis, J. L. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02743.x · Cited by 28 · see citing works
Update on the management of symptoms in schizophrenia: focus on amisulpride
Mortimer, A. M. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3949 · Cited by 27 · see citing works
Remission in the outpatient care of schizophrenia: 3-Year results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study in France
Gasquet, I., Haro, J. M., Tcherny‐Lessenot, S., Chartier, F., & Lépine, J. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.012 · Cited by 26 · see citing works
Self-citation
Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
Brugnoli, R., Novick, D., Haro, J. M., Rossi, A., Bortolomasi, M., Frediani, S., & Borgherini, G. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-83 · Cited by 25 · see citing works
Self-citation
The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series
Kim, S. H., Jung, D. C., Ahn, Y. M., & Kim, Y. S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109348174 · Cited by 23 · see citing works
Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572197 · Cited by 24 · see citing works
Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence
Kelin, K., Ascher‐Svanum, H., Lambert, T. J. R., Brnabic, A. J. M., Newton, R., Ye, W., Escamilla, Chen, K., Don, L., Montgomery, W. S., et al. (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s16800 · Cited by 20 · see citing works
Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review
Ying, J., Chew, Q. H., Wang, Y., & Sim, K. (2023) · Brain Sciences · doi:10.3390/brainsci14010006 · Cited by 19 · see citing works
Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications
Goudie, A. J., & Cole, J. C. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082904 · Cited by 18 · see citing works
Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study
Souaiby, L., Gauthier, C., Rieu, C., Krebs, M., Advenier-Iakovlev, E., & Raphaël Gaillard, B. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.01.036 · Cited by 16 · see citing works
Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population
Yu, A. P., Ben-Hamadi, R., Birnbaum, H. G., Atanasov, P. D., Stensland, M. D., & Philips, G. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802683579 · Cited by 16 · see citing works
Drug Class Review: Atypical Antipsychotic Drugs
McDonagh, M. S., Peterson, K., Carson, S., Fu, R., & Thakurta, S. (2010) · Cited by 14 · see citing works
Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
Simpson, C., AlKhadhari, S., Al Zain, N., Selim, T. D., Khan, S. M., Okasha, T. A., Tadross, T. M., & Ramy, H. A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s78788 · Cited by 13 · see citing works
Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data
Patel, R., Brinn, A., Irving, J., Chaturvedi, J., Gudiseva, S., Correll, C. U., Fusar‐Poli, P., & McGuire, P. K. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231211575 · Cited by 11 · see citing works
Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: A naturalistic 18-month follow-up study
Vita, A., Barlati, S., Deste, G., Corsini, P., Peri, L. M. D., & Sacchetti, E. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.07.006 · Cited by 8 · see citing works
Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: Evidence from a naturalistic, retrospective, 18-month follow-up study
Vita, A., Corsini, P., Bonomi, S., Cesana, B. M., & Sacchetti, E. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.010 · Cited by 6 · see citing works
Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1‐year European observational study
Kraemer, S., Chartier, F., Augendre‐Ferrante, B., Psarra, V., Dyachkova, Y., Beselin, A., & Rouillon, F. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2224 · Cited by 6 · see citing works
Studying medication adherence in patients with schizophrenia
Sultan, M. A.-R., Hashem, R. E. S., Mohsen, N., Barakat, D. H., Ryad, R. A., & Khalil, A. H. (2016) · Middle East Current Psychiatry · doi:10.1097/01.xme.0000475315.51718.d6 · Cited by 6 · see citing works
The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study
van der Lee, A. P. M., Önsesveren, I., Wierdsma, A. I., van Westrhenen, R., Beekman, A. T. F., de Haan, L., & Mulder, N. C. L. (2021) · CNS Drugs · doi:10.1007/s40263-021-00802-3 · Cited by 5 · see citing works
Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia
Ascher‐Svanum, H., Nyhuis, A. W., Faries, D. E., Heiler, L., & Kinon, B. J. (2008) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.2.3.4 · Cited by 5 · see citing works
Patients' perception of family involvement and its relationship to medication adherence for persons with schizophrenia and schizoaffective disorders
Edelman, E. M. (2010) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3df6r88 · Cited by 5 · see citing works
The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER
Thavichachart, N., Kongsakon, R., Lo, W. T.-L., Lim, L. E. C., Singh, S., Sobrevega, E. E., Banaag, C. B., Bautista, J. M. S., Evangelista, M. L., Dimatalac, B., et al. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.03016.x · Cited by 4 · see citing works
Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
Taipale, H. T., Rahman, S. G., Tanskanen, A. J., Mehtälä, J., Hoti, F. J., Jedenius, E., Enkusson, D., Levál, A., Sermon, J., Tiihonen, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58078-4 · Cited by 3 · see citing works
Reason for Clozapine Discontinuation
Cho, J.-W., Kim, W., Shin, J.-H., Kim, J.-H., Lee, J.-S., Bae, J. N., & Kim, C. E. (2016) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2016.19.1.17 · Cited by 2 · see citing works
Differences in Baseline Characteristics of Patients Treated with Olanzapine or Other Antipsychotics in Japanese Patients with Acute Schizophrenia: A 1-Year Observational Study under Routine Clinical Practice in Japan
Takahashi, M., Fujikoshi, S., Funai, J., Alev, L., & Iyo, M. (2015) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2015.53034 · Cited by 1 · see citing works
Body composition and energy expenditure in men with schizophrenia
Sharpe, J.-K. (2007) · Faculty of Health · Cited by 1 · see citing works
Tipo de antipsicótico y correlatos de la interrupción del tratamiento de antipsicóticos en el tratamiento ambulatorio de la esquizofrenia
Haro, J. M., Novick, D., Belger, M. A., Jones, P. B., & Junta Consultiva, S. O. H. O. (2006) · European psychiatry (Ed Española) · doi:10.1017/s1134066500005191
Self-citation
Estudio SOHO (Variables Relacionadas con la Salud en Pacientes Ambulatorios con Esquizofrenia): resultados a los 3 años de la suspensión del tratamiento antipsicótico y factores clínicos relacionados con ella en España
Ciudad, A., Haro, J. M., Alonso, J., Bousoño, M., Suarez, D. L., Novick, D., & Gilaberte, I. (2008) · European psychiatry (Ed Española) · doi:10.1017/s1134066500005737
Self-citation
Towards personalized treatment of clozapine
Okhuijsen‐Pfeifer, C. (2021) · doi:10.33540/870
Postpartale Psychosen und Mutter-Kind-Behandlung
Hartwich, P., & Grube, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44246-3_9
Schizophrenia
(2009) · CRC Press eBooks · doi:10.3109/9780203092835-3
Current awareness in human psychopharmacology
(2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.733
Discussion
Schmitt, L., & Cailhol, L. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)78674-8
Reinitiation of clozapine treatment
Mayerová, M., & Ustohal, L. (2023) · Klinická farmakologie a farmacie · doi:10.36290/far.2022.025
Nationwide trends in psychiatric prescription practices for drugs with putative cognitive adverse effects in schizophrenia spectrum and bipolar disorders from 2013 to 2022
Vidal, N., Frileux, S., Younès, N., Corruble, E., Passerieux, C., Brunet-Gouet, É., & Roux, P. (2026) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2026.2650543

Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Haro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 129 · see citing works
Self-citation
The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain
Ciudad, A., Haro, J. M., Alonso, J., Bousoño, M., Suarez, D. L., Novick, D., & Gilaberte, I. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.09.008 · Cited by 29 · see citing works
Self-citation
Tipo de antipsicótico y correlatos de la interrupción del tratamiento de antipsicóticos en el tratamiento ambulatorio de la esquizofrenia
Haro, J. M., Novick, D., Belger, M. A., Jones, P. B., & Junta Consultiva, S. O. H. O. (2006) · European psychiatry (Ed Española) · doi:10.1017/s1134066500005191
Self-citation
P-1263 - Antipsychotic treatment for patients with schizophrenia; patient-decided and clinician-decided discontinuations
Kroken, R. A., Mellesdal, L., Jørgensen, H. A., Wentzel‐Larsen, T., & Johnsen, E. (2012) · European Psychiatry · doi:10.1016/s0924-9338(12)75430-5
Predictors of Discontinuation of Antipsychotic Therapy in Patients with Acute Schizophrenia: A 1-Year Observational Study with More Than 1000 Patients
Takahashi, M., Fujikoshi, S., Funai, J., Alev, L., & Iyo, M. (2014) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2014.44042

Authors: Haro, J. M., Novick, D., Belger, M., & Jones, P. B.
Affiliations: Eli Lilly (United Kingdom) (GB)
University of Cambridge (GB)
Corresponding author: Haro, Josep Maria
ORCID: Haro, Josep Maria
Jones, Peter B.
Venue: European Psychiatry
Publisher: Cambridge University Press (CUP)
Published: 2006-01
Volume: 21
Issue: 1
Pages: 41-47
ISSN: 0924-9338 (ISSN-L)
1778-3585
DOI: 10.1016/j.eurpsy.2005.12.001
OpenAlex: W1976874578
Cited by: 49
References: 29
Citations by year: 2026: 1 · 2025: 1 · 2023: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 5
FWCI: 4.46
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified, 5219 d)
Locations: European Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, outpatient care, clozapine, olanzapine, quetiapine, amisulpride, alcohol dependency, mood stabilizers, involuntary admission, clinical severity, treatment-naive patients, low libido
MeSH terms: Adult, Ambulatory Care, Demography, Drug Therapy, Europe, Female, Humans, Male, Schizophrenia, Antipsychotic Agents, Treatment Refusal, Observation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks